Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Share-based Compensation (2016 - 2025)

Aethlon Medical filings provide 15 years of Share-based Compensation readings, the most recent being $72443.0 for Q1 2025.

  • On a quarterly basis, Share-based Compensation fell 47.93% to $72443.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $415234.0, a 65.95% decrease, with the full-year FY2025 number at $415234.0, down 65.95% from a year prior.
  • Share-based Compensation hit $72443.0 in Q1 2025 for Aethlon Medical, down from $89970.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $572955.0 in Q4 2023 to a low of $72443.0 in Q1 2025.
  • Median Share-based Compensation over the past 5 years was $201062.0 (2021), compared with a mean of $211019.9.
  • Biggest five-year swings in Share-based Compensation: soared 118.17% in 2023 and later plummeted 84.3% in 2024.
  • Aethlon Medical's Share-based Compensation stood at $201019.0 in 2021, then surged by 30.64% to $262613.0 in 2022, then soared by 118.17% to $572955.0 in 2023, then plummeted by 84.3% to $89970.0 in 2024, then decreased by 19.48% to $72443.0 in 2025.
  • The last three reported values for Share-based Compensation were $72443.0 (Q1 2025), $89970.0 (Q4 2024), and $113493.0 (Q3 2024) per Business Quant data.